How do PCABs compare to PPIs in terms of cost-effectiveness for payers?

PCABs carry a 3–5x price premium over generic PPIs but achieve higher first-line eradication rates, reducing retreatment costs. Payer pharmacoeconomic models suggest net savings within 18 months for H. pylori-positive populations [3]. Read More

What role does CYP2C19 genetic polymorphism play in drug selection within the Peptic Ulcer Drugs Market?

CYP2C19 poor metabolizers experience variable PPI efficacy, affecting up to 20% of the Asian population. PCABs bypass this pathway entirely, offering consistent acid suppression regardless of genotype [4]. Read More

How are biosimilar developments expected to affect the Peptic Ulcer Drugs Market beyond 2030?

Biologic-adjacent therapies targeting mucosal healing are in early-stage trials. Biosimilar entry would compress specialty pricing, though commercial impact remains limited before 2032. Read More

What procurement strategies should hospital systems adopt when evaluating PCAB formulary inclusion?

Hospitals should negotiate outcomes-based contracts tying PCAB pricing to eradication success metrics. Pilot programs in 2–3 service lines before system-wide rollout reduce financial risk [11]. Read More

How does antibiotic stewardship policy influence the Peptic Ulcer Drugs Market?

Stewardship programs restrict empiric antibiotic prescribing for H. pylori, increasing demand for susceptibility testing and tailored regimens. This trend favors PCAB-based dual therapies requiring fewer antibiotics [17]. Read More

What reimbursement challenges do PCAB manufacturers face in price-regulated European markets?

Reference pricing systems in Germany and France benchmark new drugs against generic PPI prices. Manufacturers must demonstrate incremental clinical value through health technology assessments to secure premium reimbursement [19]. Read More

How will point-of-care H. pylori diagnostics reshape prescribing in the Peptic Ulcer Drugs Market?

Rapid molecular tests delivering resistance profiles in under two hours enable targeted first-line therapy. Widespread adoption could reduce global retreatment rates from 25% to under 10% by 2032 [24]. Read More

Peptic Ulcer Drugs Market (2025 - 2035)

ID: MRFR/Pharma/1812-HCR

85 Pages

Satyendra Maurya

Last Updated: June 22, 2026

Peptic Ulcer Drugs Market Research Report Information By Pharmacological class (Proton pump inhibitors (PPs), Anti-histamines, H2 antagonists, Antacids, and Others), By Clinical (Gastric ulcers, Duodenal ulcer, and Esophageal ulcer), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Industry Forecast Till 2035

Peptic Ulcer Drugs Market

Market Size

Forecast Period2025-2035

CAGR (2025-2035)5.48%

2025 Market SizeUSD 5.71 Billion

2035 Market SizeUSD 9.74 Billion

Key Players

AstraZeneca

Takeda Pharmaceutical

Pfizer

Johnson & Johnson

Abbott Laboratories

Daiichi Sankyo

Trends

PCAB Therapeutic Class Expansion
Digital Pharmacy and E-Commerce Channel Expansion
Aging Demographics and NSAID-Driven Ulcer Incidence

Opportunities

Next-Generation PCAB Pipeline and Indication Expansion
Digital Therapeutics Integration for Adherence Optimization
Microbiome-Guided Precision Therapy

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways
3 Market Dynamics |
1. 3.1 Market Drivers Analysis | |
  1. 3.1.1 H. pylori Screening Programs and Eradication Campaigns | |
  2. 3.1.2 PCAB Therapeutic Class Expansion | |
  3. 3.1.3 Digital Pharmacy and E-Commerce Channel Expansion | |
  4. 3.1.4 Aging Demographics and NSAID-Driven Ulcer Incidence | |
  5. 3.1.5 ICU Prophylaxis Protocol Expansion | |
  6. 3.1.6 Emerging-Market Insurance Coverage Expansion | |
  7. 3.1.7 Regulatory Push Toward Safer Acid Suppression |
2. 3.2 Market Restraints Analysis | |
  1. 3.2.1 Generic Price Compression Following PPI Patent Cliffs | |
  2. 3.2.2 FDA and EMA Safety Warnings on Chronic Acid Suppression | |
  3. 3.2.3 Antibiotic Resistance Threatening Eradication Regimen Efficacy | |
  4. 3.2.4 Price Controls in Emerging Markets | |
  5. 3.2.5 OTC Switching: Reducing Prescription Revenue |
3. 3.3 Market Opportunity Analysis | |
  1. 3.3.1 Next-Generation PCAB Pipeline and Indication Expansion | |
  2. 3.3.2 Government-Funded H. pylori Eradication in Emerging Markets | |
  3. 3.3.3 Digital Therapeutics Integration for Adherence Optimization | |
  4. 3.3.4 Microbiome-Guided Precision Therapy | |
  5. 3.3.5 Private-Label and OTC Portfolio Expansion |
4. 3.4 Industry Value Chain Analysis |
5. 3.5 Porter's Five Forces Analysis
4 Global Peptic Ulcer Drugs Market Size & Forecast (2021–2035) |
1. 4.1 Historical Market Size (2021–2025) |
2. 4.2 Current & Forecast Market Size (2026–2035) |
3. 4.3 Market Size by Revenue (USD Billion) |
4. 4.4 Year-over-Year Growth Analysis
5 Segmentation Analysis |
1. 5.1 By Drug Class | |
  1. 5.1.1 Proton Pump Inhibitors | |
  2. 5.1.2 Potassium-Competitive Acid Blockers | |
  3. 5.1.3 H2-Receptor Antagonists | |
  4. 5.1.4 Antacids & Mucosal Protective Agents |
2. 5.2 By Disease Indication | |
  1. 5.2.1 Gastric Ulcer | |
  2. 5.2.2 Duodenal Ulcer | |
  3. 5.2.3 Stress-Related Mucosal Damage | |
  4. 5.2.4 NSAID-Induced Ulcer |
3. 5.3 By Distribution Channel | |
  1. 5.3.1 Hospital Pharmacies | |
  2. 5.3.2 Retail/Drug Stores | |
  3. 5.3.3 Online Pharmacies & E-Commerce
6 Regional Analysis |
1. 6.1 North America | |
  1. 6.1.1 United States | |
  2. 6.1.2 Canada | |
  3. 6.1.3 Mexico |
2. 6.2 Europe | |
  1. 6.2.1 Germany | |
  2. 6.2.2 United Kingdom | |
  3. 6.2.3 France | |
  4. 6.2.4 Italy | |
  5. 6.2.5 Spain | |
  6. 6.2.6 Nordic Countries | |
  7. 6.2.7 Russia | |
  8. 6.2.8 Rest of Europe |
3. 6.3 Asia-Pacific | |
  1. 6.3.1 China | |
  2. 6.3.2 India | |
  3. 6.3.3 Japan | |
  4. 6.3.4 South Korea | |
  5. 6.3.5 ASEAN | |
  6. 6.3.6 Rest of Asia-Pacific |
4. 6.4 South America | |
  1. 6.4.1 Brazil | |
  2. 6.4.2 Argentina | |
  3. 6.4.3 Rest of South America |
5. 6.5 Middle East & Africa | |
  1. 6.5.1 Saudi Arabia | |
  2. 6.5.2 UAE | |
  3. 6.5.3 South Africa | |
  4. 6.5.4 Egypt | |
  5. 6.5.5 Rest of MEA
7 Competitive Landscape |
1. 7.1 Market Share Analysis (2025) |
2. 7.2 Competitive Benchmarking Matrix |
3. 7.3 Company Profiles | |
  1. 7.3.1 AstraZeneca | |
  2. 7.3.2 Takeda Pharmaceutical | |
  3. 7.3.3 Pfizer | |
  4. 7.3.4 Johnson & Johnson | |
  5. 7.3.5 Abbott Laboratories | |
  6. 7.3.6 Daiichi Sankyo | |
  7. 7.3.7 Eisai Co. | |
  8. 7.3.8 Viatris | |
  9. 7.3.9 Sun Pharmaceutical Industries | |
  10. 7.3.10 Lupin Limited
8 Future Outlook & Strategic Recommendations (2026–2035) |
1. 8.1 AI-Driven Diagnostic Triage and Treatment Personalization |
2. 8.2 Microbiome Therapeutics and Companion Diagnostics |
3. 8.3 Value-Based Contracting and Outcomes-Linked Pricing |
4. 8.4 Sustainability and Green Chemistry in Pharmaceutical Manufacturing
9 Recent Developments & News
10 Frequently Asked Questions (FAQs)
11 Report Scope & Methodology |
1. 11.1 Study Period & Base Year |
2. 11.2 Data Sources & Citations |
3. 11.3 Abbreviations
12 LIST OF TABLES |
TABLE 1 Global Peptic Ulcer Drugs Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Peptic Ulcer Drugs Market — Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Global Peptic Ulcer Drugs Market — Driver Impact Analysis |
TABLE 4 Global Peptic Ulcer Drugs Market — Restraint Impact Analysis |
TABLE 5 Global Peptic Ulcer Drugs Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 6 Global Peptic Ulcer Drugs Market Size, by Disease Indication, 2021–2035 (USD Billion) |
TABLE 7 Global Peptic Ulcer Drugs Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 8 Global Peptic Ulcer Drugs Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 9 North America Peptic Ulcer Drugs Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 10 Europe Peptic Ulcer Drugs Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Asia-Pacific Peptic Ulcer Drugs Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 12 South America Peptic Ulcer Drugs Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 13 Middle East & Africa Peptic Ulcer Drugs Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 14 Competitive Benchmarking Matrix — Global Peptic Ulcer Drugs Market, 2025 |
TABLE 15 Company Profiles — Key Players, Global Peptic Ulcer Drugs Market |
TABLE 16 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 17 Report Scope & Methodology Summary |
TABLE 18 Detailed Sources and Citations |
TABLE 19 North America Peptic Ulcer Drugs Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 20 North America Peptic Ulcer Drugs Market Size, by Disease Indication, 2021–2035 (USD Billion) |
TABLE 21 North America Peptic Ulcer Drugs Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 22 Europe Peptic Ulcer Drugs Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 23 Europe Peptic Ulcer Drugs Market Size, by Disease Indication, 2021–2035 (USD Billion) |
TABLE 24 Europe Peptic Ulcer Drugs Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 25 Asia-Pacific Peptic Ulcer Drugs Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 26 Asia-Pacific Peptic Ulcer Drugs Market Size, by Disease Indication, 2021–2035 (USD Billion) |
TABLE 27 Asia-Pacific Peptic Ulcer Drugs Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 28 South America Peptic Ulcer Drugs Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 29 South America Peptic Ulcer Drugs Market Size, by Disease Indication, 2021–2035 (USD Billion) |
TABLE 30 South America Peptic Ulcer Drugs Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 31 Middle East & Africa Peptic Ulcer Drugs Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 32 Middle East & Africa Peptic Ulcer Drugs Market Size, by Disease Indication, 2021–2035 (USD Billion) |
TABLE 33 Middle East & Africa Peptic Ulcer Drugs Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 34 United States Peptic Ulcer Drugs Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 35 United States Peptic Ulcer Drugs Market Size, by Disease Indication, 2021–2035 (USD Billion) |
TABLE 36 United States Peptic Ulcer Drugs Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 37 Canada Peptic Ulcer Drugs Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 38 Canada Peptic Ulcer Drugs Market Size, by Disease Indication, 2021–2035 (USD Billion) |
TABLE 39 Canada Peptic Ulcer Drugs Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 40 Mexico Peptic Ulcer Drugs Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 41 Mexico Peptic Ulcer Drugs Market Size, by Disease Indication, 2021–2035 (USD Billion) |
TABLE 42 Mexico Peptic Ulcer Drugs Market Size, by Distribution Channel, 2021–2035 (USD Billion)
13 LIST OF FIGURES |
FIGURE 1 Global Peptic Ulcer Drugs Market — Market Dynamics Overview |
FIGURE 2 Global Peptic Ulcer Drugs Market — Value Chain Analysis |
FIGURE 3 Global Peptic Ulcer Drugs Market — Porter's Five Forces Analysis |
FIGURE 4 Global Peptic Ulcer Drugs Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 5 Global Peptic Ulcer Drugs Market Share, by Drug Class, 2025 (%) |
FIGURE 6 Global Peptic Ulcer Drugs Market Share, by Disease Indication, 2025 (%) |
FIGURE 7 Global Peptic Ulcer Drugs Market Share, by Distribution Channel, 2025 (%) |
FIGURE 8 Global Peptic Ulcer Drugs Market Share, by Region, 2025 (%) |
FIGURE 9 North America Peptic Ulcer Drugs Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 10 Europe Peptic Ulcer Drugs Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 11 Asia-Pacific Peptic Ulcer Drugs Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 12 South America Peptic Ulcer Drugs Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 13 Middle East & Africa Peptic Ulcer Drugs Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 14 Competitive Landscape — Global Peptic Ulcer Drugs Market Revenue Share, 2025 (%)

Certified Researchers

Customize Report

SEGMENTATION QUICK REFERENCE

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
Drug Class	Proton Pump Inhibitors; Potassium-Competitive Acid Blockers; H2-Receptor Antagonists; Antacids & Mucosal Protective Agents	Proton Pump Inhibitors	Potassium-Competitive Acid Blockers
Disease Indication	Gastric Ulcer; Duodenal Ulcer; Stress-Related Mucosal Damage; NSAID-Induced Ulcer	Gastric Ulcer	Stress-Related Mucosal Damage
Distribution Channel	Hospital Pharmacies; Retail/Drug Stores; Online Pharmacies & E-Commerce	Hospital Pharmacies	Online Pharmacies & E-Commerce
Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America	Asia-Pacific

MARKET SEGMENTATION OVERVIEW

By Drug Class

Sub-Segment	Key Trend
Proton Pump Inhibitors	Generic saturation compressing ASPs; dominated by volume and value
Potassium-Competitive Acid Blockers	Regulatory approvals expanding globally; fastest value growth
H2-Receptor Antagonists	Stable OTC demand; declining prescription share
Antacids & Mucosal Protective Agents	Low-cost symptomatic relief, maintaining steady volumes in emerging markets

The drug class dimension reflects a market in active transition. Established PPI dominance coexists with rapid PCAB uptake, and the pace of class migration will be the single most important determinant of value growth through 2035.

By Disease Indication

Sub-Segment	Key Trend
Gastric Ulcer	Screening program expansion, sustaining treatment volumes globally
Duodenal Ulcer	Stable prevalence with treatment standardization across markets
Stress-Related Mucosal Damage	ICU prophylaxis guidelines are broadening the treated population
NSAID-Induced Ulcer	Aging populations are driving the co-prescribing of acid suppression with NSAIDs

Indication-level demand is closely linked to epidemiological trends and clinical guideline evolution. The fastest-growing indication — stress-related mucosal damage — benefits from hospital-centric prescribing dynamics where formulary access is well established.

By Distribution Channel

Sub-Segment	Key Trend
Hospital Pharmacies	Inpatient prescribing remains the primary origination point for acid-suppression therapy.
Retail/Drug Stores	OTC self-medication and chronic refill activity sustaining brick-and-mortar volumes
Online Pharmacies & E-Commerce	Subscription models and telemedicine partnerships are driving rapid channel migration

Distribution channel dynamics increasingly favor digital fulfillment, though hospital pharmacies retain structural advantages for acute indications. The interplay between inpatient origination and outpatient channel selection will shape competitive strategy across the forecast period.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”